Utility of incorporating next generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost effectiveness analysis

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death [1]. In Asia, the incidence of lung cancer is increasing and Asia accounts for over half of new lung cancer cases diagnosed worldwide [2]. Our understanding of NSCLC has transformed with the discovery of molecular subtypes and therapeutically targetable oncogenic drivers, most notably epidermal growth factor receptor (EGFR) activating mutations, anaplastic lymphoma kinase (ALK) and ROS1 gene rearrangements [3 –5]. As a result, molecular testing for EGFR, ALK and ROS1 is now recommended for all adenocarcinoma NSCLC patients [6].

Source: Lung Cancer - November 25, 2019 Category: Cancer & Oncology Authors: Aaron C. Tan, Gillianne G.Y. Lai, Gek San Tan, Shou Yu Poon, Brett Doble, Tse Hui Lim, Zaw Win Aung, Angela Takano, Wan Ling Tan, Mei-Kim Ang, Bien Soo Tan, Anantham Devanand, Chow Wei Too, Apoorva Gogna, Boon-Hean Ong, Tina P.T. Koh, Ravindran Kanesvaran Source Type: research